Talking About Tumors

Chapter 5

Chapter 5: NET, HCC, GBM, and Interviews

Hepatocellular carcinoma, neuroendocrine tumors, glioblastoma, interviews, and ongoing topics.

← Back to episode archive

S05 E01

Hepatocellular carcinoma

Open episode on Buzzsprout

Show notes

Topics covered

  1. Etiologies and epidemiology
  2. Staging and local/regional considerations
  3. Systemic Therapy
  4. Differences in immune checkpoint sensitivity by etiology
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183
  2. 2. Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0
  3. 3. Zhu AX et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9
  4. 4. Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070
  5. 5. Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1
  6. 7. Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857
  7. 8. Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018
  8. 9. Cheng AL et al. J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030
  9. 10. Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745
  10. 11. Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S05 E02

Neuroendocrine Carcinomas

Open episode on Buzzsprout

Show notes

Topics covered

  1. Nomenclature, unique considerations
  2. Secretory Syndromes
  3. Somatostatin directed therapy
  4. Peptide Receptor Radionucleotide Therapy
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Kunz PL et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/
  2. 2. Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6
  3. 3. Strosberg J et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427
  4. 4. Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158
  5. 5. Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-2
  6. 6. Guidelines by topic | ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers
  7. 7. Pieterman CRC , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468
  8. 8. NANETS. Accessed May 1, 2025. https://nanets.net/
  9. 9. Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612
  10. 10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology